CoChat

Clinical Features and Outcomes of Women With Unstable Ischemic Heart Disease: Observations From Metabolic Efficiency With Ranolazine for Less Ischemia in Non–ST-Elevation Acute Coronary Syndromes–Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36)

Mega, Jessica L., Hochman, Judith S., Scirica, Benjamin M., Murphy, Sabina A., Sloan, Sarah, McCabe, Carolyn H., Merlini, Piera, Morrow, David A. · 2010 · Circulation
Cited by 68

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Background— The pathobiological basis of ischemic heart disease and thus the manifestations and response to therapy can differ between women and men. In prior studies, sex-based treatment differences have been observed with the antiischemic ranolazine, with a possibly diminished effect in women. Methods and Results— We conducted a prospectively planned analysis of the clinical, biomarker, angiographic, and continuous ECG features and 1-year outcomes of women with unstable ischemic heart disease randomized to ranolazine or placebo in Metabolic Efficiency With Ranolazine for Less Ischemia in Non–ST-Elevation Acute Coronary Syndromes–Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36). Compared with men (n=4269), women (n=2291) were older with more risk factors ( P <0.001). On presentation, women were less likely than men to have significant epicardial coronary artery disease (no stenosis ≥50% on angiography, 19.4% versus 8.6%; P <0.001) or elevated troponin (57.1% versus 68.9%; P <0.001). Yet, women were more likely to have an elevated B-type natriuretic peptide (47.0% versus 40.2%; P <0.001), worse median angina frequency scores (80 versus 100; P <0.001), and an ischemic episode on continuous ECG administered during the first 7 days (22.5% versus 19.3%; P =0.0025). Women and men were at similar adjusted risk for the primary end point of cardiovascular death, myocardial infarction, or recurrent ischemia (adjusted hazard ratio, 1.11; 95% confidence interval, 0.96 to 1.29; P =0.15). Ranolazine was associated with a significant reduction in recurrent ischemia in women (13.0% versus 18.2%; hazard ratio, 0.71; 95% confidence interval, 0.57 to 0.88; P =0.002). Conclusions— Women with a clinical syndrome consistent with unstable ischemic heart disease, despite having less obstructive coronary artery disease, were more likely than men to report anginal episodes and had more recorded ischemic periods on continuous ECG. In this setting, ranolazine may be a particularly useful antiischemic agent in women. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00099788.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.109.897231

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 68

Metadata

Authors
Mega, J. L., Hochman, J. S., Scirica, B. M., Murphy, S. A., Sloan, S., McCabe, C. H., Merlini, P., & Morrow, D. A.
Venue
Circulation
Published
2010-04-27
Volume
121
Issue
16
Pages
1809-1817
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W1981883618
Cited by
68
References
4
FWCI
5.52
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical Features and Outcomes of Women With Unstable Ischemic Heart Disease: Observations From Metabolic Efficiency With Ranolazine for Less Ischemia in Non–ST-Elevation Acute Coronary Syndromes–Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36). https://app.cochat.ai/papers/10.1161/circulationaha.109.897231
The paper
Mega, J. L., Hochman, J. S., Scirica, B. M., Murphy, S. A., Sloan, S., McCabe, C. H., Merlini, P., & Morrow, D. A. (2010). Clinical Features and Outcomes of Women With Unstable Ischemic Heart Disease: Observations From Metabolic Efficiency With Ranolazine for Less Ischemia in Non–ST-Elevation Acute Coronary Syndromes–Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36). Circulation. https://doi.org/10.1161/circulationaha.109.897231

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.